Esperion Therapeutics (ESPR) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ESPR shares.
View ESPR analyst ratings or view top-rated stocks.

9 equities research analysts have issued 12 month target prices for Esperion Therapeutics' stock. Their ESPR share price forecasts range from $4.00 to $22.00. On average, they predict the company's stock price to reach $10.88 in the next twelve months. This suggests a possible upside of 1,035.2% from the stock's current price.
View analysts price targets for ESPR or view top-rated stocks among Wall Street analysts.

Esperion Therapeutics' stock was trading at $6.23 at the beginning of 2023. Since then, ESPR stock has decreased by 84.6% and is now trading at $0.9580.
View the best growth stocks for 2023 here.

Esperion Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 16,460,000 shares, an increase of 8.4% from the August 31st total of 15,180,000 shares. Based on an average daily volume of 3,500,000 shares, the short-interest ratio is presently 4.7 days. Approximately 15.5% of the shares of the stock are sold short.
View Esperion Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our ESPR earnings forecast.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings results on Tuesday, August, 1st. The biopharmaceutical company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.15. The biopharmaceutical company had revenue of $25.79 million for the quarter, compared to the consensus estimate of $24.64 million. The company's revenue was up 36.9% on a year-over-year basis. During the same period last year, the business earned ($1.05) earnings per share.

20 employees have rated Esperion Therapeutics Chief Executive Officer Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Shares of ESPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ESPR stock can currently be purchased for approximately $0.96.

Esperion Therapeutics (NASDAQ:ESPR) has a market capitalization of $102.50 million and generates $75.47 million in revenue each year. The biopharmaceutical company earns $-233,660,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis.

The company employs 199 workers across the globe.

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The official website for the company is www.esperion.com. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at ir@esperion.com.